Regadenoson (DrugBank: Regadenoson)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 58 | Hypertrophic cardiomyopathy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03249272 (ClinicalTrials.gov) | September 5, 2017 | 8/8/2017 | Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve | Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve | Hypertrophic Cardiomyopathy;Non-ischemic Dilated Cardiomyopathy;Microvascular Ischaemia of Myocardium | Drug: Regadenoson;Drug: Adenosine | Duke University | NULL | Terminated | 18 Years | N/A | All | 31 | Phase 4 | United States |